Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I
- PMID: 9444886
Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I
Abstract
Background: Left ventricular hypertrophy (LVH) is a generalized adaptation to altered myocardial load. Hypertension induces significant increases in ventricular IGF-I gene expression that occur coordinately with development of LVH. To test whether IGF-I promotes initiation of LVH, we examined ventricular IGF-I mRNA content in spontaneously hypertensive rats (SHRs) treated with antihypertensive drugs that limit or permit LVH.
Methods: Prehypertensive SHRs were left untreated or treated with enalapril, nifedipine, or hydralazine. Systolic blood pressure (SBP), hypertrophy index (ventricular weight/body weight), and ventricular IGF-I mRNA levels were examined 2, 4, and 6 weeks after beginning therapy in the experimental groups.
Results: Systolic blood pressure reached hypertensive levels after 2 weeks in untreated animals, and was controlled in the treated animals. The hypertrophy index in untreated animals was significantly elevated at 4 weeks. By 6 weeks, the hypertrophy indices of both the enalapril- and nifedipine-treated groups were significantly lower than that of the untreated group. In contrast, the hypertrophy index of the hydralazine-treated animals remained comparable to that of the untreated animals. By 4 weeks, IGF-I mRNA levels in the enalapril- and nifedipine-treated groups were significantly lower than those in the untreated and hydralazine-treated groups.
Conclusions: We conclude that: (1) antihypertensive drugs that reduce LVH blunt ventricular IGF-I mRNA content; and (2) the hemodynamic effects of antihypertensives may be dissociated from their ability to promote or limit a hypertrophic response. The clear association of LVH with ventricular IGF-I mRNA content suggests that IGF-I is an important determinant of ventricular growth. Our data also suggest that angiotensin-converting enzyme inhibitors and calcium channel blockers may reduce LVH by inhibiting cardiac IGF-I gene expression.
Similar articles
-
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.Minerva Cardioangiol. 2002 Jun;50(3):169-74. Minerva Cardioangiol. 2002. PMID: 12107398 Review.
-
Effects of enalapril and hydralazine treatment and withdrawal upon cardiovascular hypertrophy in stroke-prone spontaneously hypertensive rats.J Hypertens. 1992 Sep;10(9):919-28. J Hypertens. 1992. PMID: 1328373
-
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.J Lab Clin Med. 2000 Apr;135(4):353-9. doi: 10.1067/mlc.2000.105617. J Lab Clin Med. 2000. PMID: 10779052
-
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].Zhonghua Yi Xue Za Zhi. 2005 Nov 30;85(45):3199-204. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16405840 Chinese.
-
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.Blood Press Suppl. 1994;2:35-40. Blood Press Suppl. 1994. PMID: 8061844 Review.
Cited by
-
Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil.Mol Cell Biochem. 2000 Oct;213(1-2):111-8. doi: 10.1023/a:1007120332587. Mol Cell Biochem. 2000. PMID: 11129949
-
Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy.Curr Hypertens Rep. 2000 Jun;2(3):260-70. doi: 10.1007/s11906-000-0009-z. Curr Hypertens Rep. 2000. PMID: 10981159 Review.
-
Cardiovascular effects of growth hormone.Endocrine. 2000 Apr;12(2):153-61. doi: 10.1385/ENDO:12:2:153. Endocrine. 2000. PMID: 10905375 Review. No abstract available.
-
Intravenous IGF-I receptor antisense reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats.Br J Pharmacol. 2005 Dec;146(7):935-41. doi: 10.1038/sj.bjp.0706378. Br J Pharmacol. 2005. PMID: 16205725 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical